This webinar will discuss a new method that relies on Crystal digital PCR™ from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

The new method relies on target detection by Stilla’s Crystal dPCR with the naica™ system. The process allows for single nucleotide variant detection in up to 20,000 partitions per reaction, with up to 48 reactions per run.

Elise Gourri of the Blood Transfusion Service Zurich will discuss the validation and implementation of the naica™ system for routine chimerism monitoring.

Her presentation will discuss how the Department of Molecular Diagnostics and Flow Cytometry confirmed the reliability of the dPCR platform on samples from previously monitored patients as well as external quality assessment samples. They could provide reproducible quantification of the minor allele, even below 0.25 percent, and, notably, the clinically required 0.5 percent minor allele sensitivity was achieved with only 5 ng of input DNA.

The webinar will detail the department’s conclusion that the naica™ system is fast, convenient, and highly accurate.

By Elise Gourri, Scientist at the Department of Molecular Diagnostics and Flow Cytometry (MOC), Blood Transfusion Service Zurich, Swiss Red Cross & Viviane Sternkopf, Application Specialist at Stilla Technologies.